TR200103693T2 - Yeni formülasyon - Google Patents

Yeni formülasyon

Info

Publication number
TR200103693T2
TR200103693T2 TR2001/03693T TR200103693T TR200103693T2 TR 200103693 T2 TR200103693 T2 TR 200103693T2 TR 2001/03693 T TR2001/03693 T TR 2001/03693T TR 200103693 T TR200103693 T TR 200103693T TR 200103693 T2 TR200103693 T2 TR 200103693T2
Authority
TR
Turkey
Prior art keywords
dosage form
extract
omeprazole
new formulation
basic
Prior art date
Application number
TR2001/03693T
Other languages
English (en)
Inventor
Johan Lundberg Per
Sj�blom Brita
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200103693T2 publication Critical patent/TR200103693T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Yari geçirgen bir zar ile kaplanmis bir öz maddesinden olusan agizdan alinan bir dozaj biçimi, burada öz maddesi bir tane ya da daha fazla bazik yardimci maddeler ile, bir tane ya da daha fazla sisirici ajan ile ve istege bagli olarak farmasötik olarak kabul edilebilen katki maddeleri ile karisim halinde olan, omeprazol grubundan, bunun bazik bir tuzundan, S-omeprazol'den ve bunun bazik bir tuzundan seçilmis olan bir aktif maddeyi içerir, ve dozaj biçimi enterik kaplamali degildir.
TR2001/03693T 1999-06-22 2000-06-20 Yeni formülasyon TR200103693T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902386A SE9902386D0 (sv) 1999-06-22 1999-06-22 New formulation

Publications (1)

Publication Number Publication Date
TR200103693T2 true TR200103693T2 (tr) 2002-05-21

Family

ID=20416209

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03693T TR200103693T2 (tr) 1999-06-22 2000-06-20 Yeni formülasyon

Country Status (29)

Country Link
EP (1) EP1191926B1 (tr)
JP (1) JP2003502359A (tr)
KR (1) KR100717661B1 (tr)
CN (1) CN1243547C (tr)
AT (1) ATE291901T1 (tr)
AU (1) AU778158B2 (tr)
BR (1) BR0011894A (tr)
CA (1) CA2376226C (tr)
CZ (1) CZ20014579A3 (tr)
DE (1) DE60019116T2 (tr)
DK (1) DK1191926T3 (tr)
EE (1) EE200100693A (tr)
ES (1) ES2235912T3 (tr)
HK (1) HK1044480B (tr)
HU (1) HUP0201489A3 (tr)
IL (2) IL146818A0 (tr)
IS (1) IS6209A (tr)
MX (1) MXPA01012636A (tr)
NO (1) NO20016346L (tr)
NZ (1) NZ516186A (tr)
PL (1) PL352873A1 (tr)
PT (1) PT1191926E (tr)
RU (1) RU2240110C2 (tr)
SE (1) SE9902386D0 (tr)
SK (1) SK285326B6 (tr)
TR (1) TR200103693T2 (tr)
UA (1) UA73302C2 (tr)
WO (1) WO2000078293A1 (tr)
ZA (1) ZA200109803B (tr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
WO2004075881A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005027876A1 (en) * 2003-08-28 2005-03-31 Ranbaxy Laboratories Limited Pharmaceutical compositions of benzimidazole and processes for their preparation
WO2005020954A2 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1789037A4 (en) * 2004-08-23 2010-01-20 Synergy Pharmaceuticals Pte Lt GASTRIC THERAPIES AND THEIR COMPOSITIONS
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
JP5095615B2 (ja) 2005-06-27 2012-12-12 バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ ブプロピオン塩の放出調整製剤
US20090175959A1 (en) * 2005-12-28 2009-07-09 Takeda Pharmaceutical Company Limited Controlled Release Solid Preparation
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
ES2511792T3 (es) 2006-07-25 2014-10-23 Vecta Ltd. Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
EP2344139A1 (en) 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE
CN109908099B (zh) 2011-05-13 2021-10-29 Eb Ip希博里塔布斯有限责任公司 药物递送系统
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
WO2015102745A1 (en) 2013-12-31 2015-07-09 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
RU2614730C1 (ru) * 2016-02-05 2017-03-28 Игорь Юрьевич Чичерин Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
US10736855B2 (en) * 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
JP6462625B2 (ja) * 2016-04-06 2019-01-30 ニプロ株式会社 カルシウムブロッカーを含有する錠剤
JP6426115B2 (ja) * 2016-04-06 2018-11-21 ニプロ株式会社 カルシウムブロッカーを含有する固形医薬組成物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DE69729950T2 (de) * 1996-11-06 2005-07-28 Wockhardt Europe Ltd. Arzneimittel-Zuführsystem mit verzögerter Freisetzung für säurelabile Arzneistoffe
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
ES2362418T3 (es) * 1997-12-08 2011-07-05 Nycomed Gmbh Nueva forma de supositorio que comprende un compuesto activo ácido-lábil.
CA2507743C (en) * 1998-08-12 2008-03-18 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles

Also Published As

Publication number Publication date
SK18252001A3 (sk) 2002-09-10
DE60019116D1 (de) 2005-05-04
MXPA01012636A (es) 2002-06-21
IL146818A (en) 2007-10-31
CN1356893A (zh) 2002-07-03
EE200100693A (et) 2003-02-17
WO2000078293A1 (en) 2000-12-28
SK285326B6 (sk) 2006-11-03
PT1191926E (pt) 2005-07-29
KR100717661B1 (ko) 2007-05-14
ATE291901T1 (de) 2005-04-15
CZ20014579A3 (cs) 2002-05-15
NO20016346D0 (no) 2001-12-21
RU2240110C2 (ru) 2004-11-20
CN1243547C (zh) 2006-03-01
ES2235912T3 (es) 2005-07-16
DK1191926T3 (da) 2005-06-13
NZ516186A (en) 2003-11-28
UA73302C2 (en) 2005-07-15
HK1044480A1 (en) 2002-10-25
HUP0201489A2 (hu) 2002-11-28
CA2376226A1 (en) 2000-12-28
AU778158B2 (en) 2004-11-18
CA2376226C (en) 2009-10-20
DE60019116T2 (de) 2006-02-09
JP2003502359A (ja) 2003-01-21
ZA200109803B (en) 2003-02-28
KR20020012002A (ko) 2002-02-09
HUP0201489A3 (en) 2004-05-28
SE9902386D0 (sv) 1999-06-22
HK1044480B (zh) 2005-08-26
IS6209A (is) 2001-12-21
EP1191926A1 (en) 2002-04-03
BR0011894A (pt) 2002-04-02
NO20016346L (no) 2002-02-18
IL146818A0 (en) 2002-07-25
PL352873A1 (en) 2003-09-08
EP1191926B1 (en) 2005-03-30
AU6034400A (en) 2001-01-09

Similar Documents

Publication Publication Date Title
TR200103693T2 (tr) Yeni formülasyon
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
RS20090086A (en) Nucleoside analogs with carobxamidine modified monocyclic base
NO20012222L (no) Farmasöytisk formulering innbefattende omeprazol
SE8804629D0 (sv) New therapeutically active compounds
RS50814B (sr) Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)- heksadeka-2(11),3,5,7,9-pentaena
TR199802698T2 (tr) Valsartanin kati oral doz formlari.
ATE218580T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
GEP20043315B (en) Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof
NO961136L (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
BR0115516A (pt) Composição farmacêutica, e, método para prevenir ou tratar hipertensão
EE9900144A (et) Välispidine lokaalanesteetikum
SE8804628D0 (sv) New compounds
DE60128100D1 (de) Analgetisches arzneimittel
ES2024993A6 (es) Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
DK1154776T3 (da) Farmaceutisk sammensætning, indeholdende desoxypeganin til behandling af alkoholisme
IT1318424B1 (it) Composti con attivita' anti-hiv.
TR199903001T2 (tr) 2-{4-[4-(4,5-Dikloro-2-metilimidazol-1-YL) Butil]-1-piperazinil}-5-floropirimidin, hazirlanisi ve tedavi edici olarak kullanimi.
GB0006897D0 (en) Medicaments